Biotech
Feuerstein's Biotech-Stock Mailbag
10/06/07 - 11:24 AM EDT
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Drug Data Lift Hollis-Eden
- Erbitux Gets Label Update
- Best Case for PDL BioPharma's Sale
- Sneak a Peek at Promising Hep C Stocks
- Feuerstein's Biotech-Stock Mailbag
- Onyx Pharma Poised to Crack Asian Market
- Del.icio.us
- Digg
- StumbleUpon
Welcome to the Columbus Day Weekend edition of the Biotech Mailbag. True story: When I lived in San Francisco, my kids didn't get the day off from school for Columbus Day. Instead, they spent the day celebrating "Indigenous Peoples Day." As my daughter explained to me, you can't "discover" a new world when plenty of people live there already. Now we live in Boston and let's just say that my kids' new school has a different, more traditional take on ol' Chris Columbus. They get the day off, too. The West Coast-East Coast Columbus perception thing is interesting. But enough about 15th-century European explorers. Let's get to your email. This week:
- Biogen IdecBIIB
- Neurocrine BiosciencesNBIX
- Vion PharmaceuticalsVION
- Panacos PharmaceuticalsPANC
- Discovery LabsDSCO.
John C. writes: "Is Biogen Idec a good buy right now? It's up over 34% for the year. Do you think it will keep trending upward? I don't see a lot of insider buying." Biogen Idec has had a rock-star year. As I write this, with shares trading at $65.66, the stock is up 33% year to date, up 53% from its March low. No other big-cap biotech stock has performed as well in 2007. Gilead SciencesGILD and CelgeneCELG have done very well, but they only take the silver and bronze; Biogen Idec is the gold medalist.
Shares jump more than 30%.
The FDA approves a labeling update for the drug as a treatment for colon cancer.
The sum of the company's parts won't get shareholders their rightful value.
Biotechs offer a glimpse of study data ahead of next month's huge Boston meeting.
This week, updates on Dendreon and Medarex.
Its Nexavar cancer drug may find a huge new market.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
